Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H14Cl2N2O |
| Molecular Weight | 273.158 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC1=C(Cl)C(Cl)=C(C=C1)C#N)C(C)(C)O
InChI
InChIKey=KYBPRVBQMUAOFG-ZETCQYMHSA-N
InChI=1S/C12H14Cl2N2O/c1-7(12(2,3)17)16-9-5-4-8(6-15)10(13)11(9)14/h4-5,7,16-17H,1-3H3/t7-/m0/s1
| Molecular Formula | C12H14Cl2N2O |
| Molecular Weight | 273.158 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:46:59 GMT 2025
by
admin
on
Mon Mar 31 21:46:59 GMT 2025
|
| Record UNII |
G6UPC5EU71
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
162623750
Created by
admin on Mon Mar 31 21:46:59 GMT 2025 , Edited by admin on Mon Mar 31 21:46:59 GMT 2025
|
PRIMARY | |||
|
G6UPC5EU71
Created by
admin on Mon Mar 31 21:46:59 GMT 2025 , Edited by admin on Mon Mar 31 21:46:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: A Single-center, Randomized, Blinded, Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in Single and Repeat Doses, With and Without Food, in Healthy Male Subjects
Purpose: This study is the first administration of GSK2849466 in humans. This will be a single centre, randomized, double-blind, placebo-controlled study, to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2849466, given as single and repeat oral doses up to 14 days to healthy male subjects. Part A will be a randomized placebo controlled and 4-way crossover study. It will include two cohorts of 8 subjects each. In each cohort there will be 4 study periods each approximately of 1 week including 6 days of washout.
|
||
|
ACTIVE MOIETY |
Originator: GlaxoSmithKline; Mechanism of Action: Selective androgen receptor modulator; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Discontinued for Cachexia, Heart failure; Most Recent Events: 23 Jun 2014 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers presented at the Joint Meeting of the 16th International Congress of Endocrinology and the 96th Annual Meeting of the Endocrine Society (ICE/ENDO-2014), 01 Feb 2014 Discontinued - Phase-I for Cachexia (In volunteers) in USA (PO) (GlaxoSmithKline pipeline, February 2014), 01 Feb 2014 Discontinued - Phase-I for Heart failure in USA (PO) (GlaxoSmithKline pipeline, February 2014)
|
